Combination of chemotherapy and immunotherapy

PreclinicalSmall molecule

GGuangzhou University of Traditional Chinese Medicine

Combination of chemotherapy and immunotherapy is one of 54 small molecule programs targeting Lung Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerRecruiting

Lung CancerPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Treatment

1 10

Vidaza

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT07337096

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Electro-acupuncture Plus PD-1 Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer: A Randomized Trial

Recruiting·GGuangzhou University of Traditional Chinese Medicine·Preclinical·NCT07337096·424 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Combination of chemotherapy and immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combination of chemotherapy and immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combination of chemotherapy and immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGuangzhou University of Traditional Chinese Medicine

Combination of chemotherapy and immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News